<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05054218</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-21536</org_study_id>
    <nct_id>NCT05054218</nct_id>
  </id_info>
  <brief_title>COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients</brief_title>
  <official_title>Immunogenicity of a Third Dose of mRNA-1273 Vaccine (Moderna) Among Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ModernaTX, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators will evaluate the immunogenicity of a third dose of mRNA-1273 SARS-CoV-2&#xD;
      vaccine among cancer patients receiving the recommended third vaccine dose&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2021</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>1. The level of anti-SARS-CoV-2 Spike (S)-specific neutralizing antibody (nAb) 28 days post-dose 3</measure>
    <time_frame>28 days</time_frame>
    <description>The level of anti-SARS-CoV-2 Spike (S)-specific neutralizing antibody (nAb) up to study day 28 will be measured by specific neutralizing antibody and serum assays</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-SARS-CoV-2 Spike (S)-specific neutralizing antibody (nAb) 6 months post-dose 3</measure>
    <time_frame>6 months</time_frame>
    <description>The level of anti-SARS-CoV-2 Spike (S)-specific neutralizing antibody (nAb) up to study month 6 will be measured by specific neutralizing antibody and serum assays</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-SARS-CoV-2 Spike (S)-GMT Ab 28 days post-dose 3</measure>
    <time_frame>28 days</time_frame>
    <description>The level of anti-SARS-CoV-2 Spike (S)-GMT Ab up to study day 28 will be measured by specific neutralizing antibody and serum assays</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-SARS-CoV-2 Spike (S)-GMT Ab 6 months post-dose 3</measure>
    <time_frame>6 months</time_frame>
    <description>The level of anti-SARS-CoV-2 Spike (S)-GMT Ab up to study month 6 will be measured by specific neutralizing antibody and serum assays</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Level antibodies that block the binding of ACE2 to RBD antigens from 10 SARS-CoV-2 variants of concern 28 days post-dose 3</measure>
    <time_frame>28 days</time_frame>
    <description>The level antibodies that block the binding of ACE2 to RBD antigens from 10 SARS-CoV-2 variants of concern up to study day 28 will be measured by specific neutralizing antibody and serum assays</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Level antibodies that block the binding of ACE2 to RBD antigens from 10 SARS-CoV-2 variants of concern 6 months post-dose 3</measure>
    <time_frame>6 months</time_frame>
    <description>The level antibodies that block the binding of ACE2 to RBD antigens from 10 SARS-CoV-2 variants of concern up to study month 6 will be measured by specific neutralizing antibody and serum assays</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Solicited local and systemic adverse reactions (ARs) post-dose 3 up to study day 20</measure>
    <time_frame>Up to 20 days</time_frame>
    <description>Investigators will measure solicited local and systemic adverse reactions (ARs) at day 14 (+/- 5 days) post 3rd dose of vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solicited local and systemic adverse reactions (ARs) post-dose 3 up to study day 40</measure>
    <time_frame>Up to 42 days</time_frame>
    <description>Investigators will measure solicited local and systemic adverse reactions (ARs) at day 28 (+ 14 days) post 3rd dose of vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who experienced Serious Adverse Events and Adverse Events</measure>
    <time_frame>Baseline thru up to 6 months</time_frame>
    <description>Participants able to safely tolerate a 3rd dose of mRNA-1273 vaccine as measured by adverse events and serious adverse events.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Covid19</condition>
  <condition>SARS-CoV2 Infection</condition>
  <arm_group>
    <arm_group_label>Participants who receive 3rd dose of mRNA-1273 SARS-CoV-2 vaccine</arm_group_label>
    <description>Cancer patients who have already received their 1st and 2nd doses of mRNA-1273 SARS-CoV-2 vaccine will receive a 3rd dose of the vaccine. The volume of vaccine injected will be 0.5 mL, containing a 100-μg dose of mRNA-1273.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mRNA-1273</intervention_name>
    <description>Participants will receive a 0.5 mL injection of the vaccine that contains a 100-μg dose of mRNA1273. The vaccine will be administered into the deltoid muscle.</description>
    <arm_group_label>Participants who receive 3rd dose of mRNA-1273 SARS-CoV-2 vaccine</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood Draw: One (1) 10 ml tiger-top tube Blood Draw: Two (2) 8 ml CPT tubes&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients of Moffitt Cancer Center who have completed their two-dose series of the mRNA-1273&#xD;
        vaccine prior to March 31, 2021.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  Is a cancer patient enrolled in the Cancer Patient Immune Response to COVID-19 Vaccine&#xD;
             study (a basic science study) MCC 21138 or who has completed the two mRNA-1273 vaccine&#xD;
             series prior to March 31, 2021.&#xD;
&#xD;
          -  Understands, agrees and is able to comply with the study procedures and provides&#xD;
             written informed consent.&#xD;
&#xD;
          -  Has no known or suspected allergy or history of anaphylaxis, urticaria, or other&#xD;
             significant adverse reactions to the vaccine or its excipients.&#xD;
&#xD;
          -  Has not received more or less than 2 doses of mRNA-1273 vaccine&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants who will not return for the third vaccine dose&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Giuliano, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moffitt Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martha Abrahamsen</last_name>
    <phone>813-745-6055</phone>
    <email>Martha.Abahamsen@moffitt.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Giuliano, PhD</last_name>
    <phone>813-745-6820</phone>
    <email>Anna.Giuliano@moffitt.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martha Abrahamsen</last_name>
      <phone>813-745-6055</phone>
      <email>Martha.Abrahamsen@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Anna Giuliano, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffrey Lancet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://moffitt.org/clinical-trials-research/clinical-trials/</url>
    <description>Moffitt Cancer Center Clinical Trial Search</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 14, 2021</study_first_submitted>
  <study_first_submitted_qc>September 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunogenicity</keyword>
  <keyword>Antibodies</keyword>
  <keyword>Vaccine Adverse Events</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

